Osborne Clarke has advised the shareholders of leading orthopaedic company, Corin, on the majority stake acquisition by global investment firm Permira.
Following five years of outstanding growth, Corin is one of the fastest growing orthopaedic firms. The substantial investment is expected to fuel the next stage of Corin’s development. Chief Executive Stefano Alfonsi and the management team will continue to lead Corin and will remain significant investors in the Company alongside the Permira funds.
Headquartered in Cirencester, UK, Corin is an international orthopaedic company with a direct presence in a majority of the world’s orthopaedic markets and a track record of strong double-digit growth. Corin aims to revolutionise orthopaedics by gaining, understanding and sharing insight at every stage of the arthroplasty experience. This unique combination of shared knowledge and clinically-proven implants delivers better outcomes and maximise healthcare value for patients, surgeons and healthcare providers.
An Osborne Clarke team led by Corporate Partner Alisdair Livingstone (Picture) advised the shareholders on the transaction. Alisdair was assisted by Associate Director Chris Yeo, Senior Associate James Taylor and Associate Isaac Paine (corporate), Legal Director David Nisbet (tax) and Associate Alistair Godwin (tax) with support from healthcare specialist Bleddyn Rees (Osborne Clarke Consultant).
Involved fees earner: Alistair Godwin – Osborne Clarke; Alisdair Livingstone – Osborne Clarke; David Nisbet – Osborne Clarke; Isaac Paine – Osborne Clarke; Bleddyn Rees – Osborne Clarke; James Taylor – Osborne Clarke; Chris Yeo – Osborne Clarke;
Law Firms: Osborne Clarke;
Clients: Corin Orthopaedics Holdings Limited;